Tech and Pharma Alliance Drives Patient-Centric Drug Development
Citizen Health Collaborates with UCB to Leverage AI and Real-World Data in Treating Epilepsy and Rare Diseases
The organization Citizen Health has entered into a multi-year strategic partnership with the pharmaceutical company UCB to expedite drug development across epilepsy and five other rare diseases.
Patient-Focused Research Model:
This collaboration merges Citizen Health’s AI-based patient insights and advocacy networks with UCB’s drug development expertise, aimed at improving patient outcomes.
Under the agreement, Citizen Health members who consent to share their health information will form patient groups for pre-clinical work through post-marketing surveillance, participating in the complete drug discovery and development journey with UCB.
-
Real-World Data: The partnership creates opportunities for patients to contribute real-world data and participate in clinical trials.
-
Transparency and Trust: The companies are prioritizing transparent and simplified patient consent processes to enhance trust and understanding.
Key Focus Area: Epilepsy:
Epilepsy is a primary area of focus for Citizen Health’s user community. The brain disorder affects approximately three million adults and nearly half a million children in the U.S., with annual healthcare costs exceeding $5 billion.
Expansion and Innovation Plans:
In addition to clinical research, Citizen Health and UCB will jointly develop experimental business models and up to three new AI use cases, focusing on secure, consumer-oriented, and technology-driven healthcare.
The Citizen Health CEO expressed pride in partnering with UCB, recognizing them as a company that deeply understands the needs of rare disease patients and is committed to advancing more efficient, patient-driven research models.
Source: https://www.pharmaceutical-technology.com/news/citizen-health-ucb-epilepsy/?cf-view
